Article by Caleb McMillan, Cannabis Life Network
Now is the time to short Aurora Cannabis.
“But they just merged with MedReleaf, they’re the biggest cannabis company in the world!”
Most LPs are losing money. Supported by the stock market that’s fuelled by cheap money from the US Federal Reserve, LP valuations aren’t reflective of true underlying values. Whatever profits they do manage are erratic and irregular.
And they know this. Owners and investors in LPs realize the Canadian market is too small and so make promises of foreign markets. But these are pipe dreams until the alarm clock sounds.
And unfortunately for them, when the alarm rings, it won’t be to the tune of opening European markets. It’ll be the economic crash bubbling under the surface.
Hence, why LPs like Aurora keep consolidating. First, CanniMed Therapeutics Inc. for $1.2-billion in January. Now, it’s MedReleaf for $3.2-billion.
None of these mergers are worth the price. When asked what metrics he used to value these mergers, Aurora CEO Terry Booth replied, “Metrics …” then trailed off, before giving his final answer: “That’s our secret.”
Not much has been written about the Ibogaine Effect as a serious factor in the Aurora acquisitions…
Chief commercial officer Cam Battley didn’t have much insight to save Booth. He said, “We don’t have an exact calculation of the synergies.” But assured us everything was hunky-dory.